Janssen Search
Search results
Janssen Provides Portfolio Update
Mar 29, 2023 United States RARITAN, N.J., March 29, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson disclosed today that following a review of its portfolio to prioritize the most transformational assets for ongoing investment, and an ...
Johnson & Johnson spotlights nipocalimab at FMF Congress 2024 – the first and only FcRn blocker to be studied in maternal fetal diseases
Jun 27, 2024 The Phase 3 AZALEA and Phase 3 FREESIA clinical studies are enrolling pregnant individuals who are at risk for severe HDFN and FNAIT These rare and potentially life-threatening alloantibody diseases affecting pregnant individuals and their ...
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
Jun 28, 2024 Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients First-and-only FcRn blocker to demonstrate superiority in activities of daily living (MG-ADL ...
Rheumatology – Treating Rheumatoid Arthritis
Rheumatology: Leveraging Expertise in Biomarkers and Co-Diagnostics to Personalize Medicine For more than a decade, Janssen has been providing patients and physicians with important therapies to treat rheumatoid arthritis (RA) and other rheumatic diseases ...
Tumor Microenvironment in Oncology
Tumor Microenvironment We focus our efforts on a clearly defined scientific approach. Evolving Tumor Microenvironment Strategy Our evolving strategy centers on innovative approaches to drug development based on a deep understanding of the critical ...
Sustainability – Overview
Helping People Live Longer, Happier, Healthier Lives Sustainability encompasses all of the ways in which we impact the world—by advancing human health and well-being, safeguarding the planet, keeping our business strong and conducting business responsibly ...
Daniel De Schryver
DANIEL DE SCHRYVER PATIENT ENGAGEMENT & ADVOCACY LEAD EUROPE, MIDDLE-EAST AND AFRICA Daniel De Schryver is Patient Engagement & Advocacy Lead for Europe, Middle East and Africa (EMEA). In this function, Daniel is part of a global multi-functional ...
Peter Ronco
PETER RONCO HEAD GLOBAL DEVELOPMENT Peter Ronco is responsible for leading the Global Development organization in delivering the portfolio on time, within budget, and with robust quality while continuously improving to optimize efficiency and the patient ...
Beth Ann Thomas
BETH ANN THOMAS DIRECTOR, BUSINESS OPERATIONS JANSSEN BIOTHERAPEUTICS Beth Ann Thomas is Director of Business Operations for Janssen BioTherapeutics (JBIO), the biotherapeutics engine of Janssen Research & Development. She is responsible for ensuring ...
Natural Language Processing
Today, 80 percent of the world's data is unstructured. Our deep expertise in natural language processing (NLP) empowers our scientists to make use of data and insights extracted from this wealth of data. Natural Language Processing The use and ...